CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Simple item page
dc.contributor.authorMohty, Mohamad
dc.contributor.authorGautier, Jordan
dc.contributor.authorMalard, Florent
dc.contributor.authorAljurf, Mahmoud Deeb
dc.contributor.authorBazarbachi, Ali Abdul Hamid
dc.contributor.authorChabannon, Christian
dc.contributor.authorKharfan-Dabaja, M. A.
dc.contributor.authorSavani, Bipin N.
dc.contributor.authorHuang, He
dc.contributor.authorKenderian, Saad Sirop Irop
dc.contributor.authorNagler, Arnon
dc.contributor.authorPerales, Miguel Ángel
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:55:34Z
dc.date.available2025-01-24T11:55:34Z
dc.date.issued2019
dc.description.abstractThe approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives. © 2019, The Author(s), under exclusive licence to Springer Nature Limited.
dc.identifier.doihttps://doi.org/10.1038/s41375-019-0615-5
dc.identifier.eid2-s2.0-85074800931
dc.identifier.pmid31690821
dc.identifier.urihttp://hdl.handle.net/10938/31210
dc.language.isoen
dc.publisherSpringer Nature
dc.relation.ispartofLeukemia
dc.sourceScopus
dc.subjectAntigens, cd19
dc.subjectAntigens, neoplasm
dc.subjectBiomarkers, tumor
dc.subjectClinical trials as topic
dc.subjectGenetic engineering
dc.subjectHumans
dc.subjectImmunotherapy, adoptive
dc.subjectLeukemia, b-cell
dc.subjectLymphoma, b-cell
dc.subjectReceptors, chimeric antigen
dc.subjectT-lymphocytes
dc.subjectTreatment outcome
dc.subjectAxicabtagene ciloleucel
dc.subjectCyclophosphamide
dc.subjectFludarabine
dc.subjectLisocabtagene maraleucel
dc.subjectTisagenlecleucel t
dc.subjectTocilizumab
dc.subjectCd19 antigen
dc.subjectCd19 molecule, human
dc.subjectTumor antigen
dc.subjectTumor marker
dc.subjectAcute lymphoblastic leukemia
dc.subjectB cell leukemia
dc.subjectB cell lymphoma
dc.subjectCancer survival
dc.subjectChimeric antigen receptor t-cell immunotherapy
dc.subjectDiffuse large b cell lymphoma
dc.subjectDrug efficacy
dc.subjectEvidence based medicine
dc.subjectHuman
dc.subjectLarge cell lymphoma
dc.subjectLymphocytic lymphoma
dc.subjectNeurotoxicity
dc.subjectNonhodgkin lymphoma
dc.subjectOverall survival
dc.subjectPhysician
dc.subjectPriority journal
dc.subjectProgression free survival
dc.subjectReview
dc.subjectAdoptive immunotherapy
dc.subjectAdverse event
dc.subjectClinical trial (topic)
dc.subjectGenetics
dc.subjectImmunology
dc.subjectMetabolism
dc.subjectMortality
dc.subjectProcedures
dc.subjectT lymphocyte
dc.titleCD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2019-7139.pdf
Size:
784.85 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine